Amgen (AMGN) Projected to Post Quarterly Earnings on Thursday

Amgen (NASDAQ:AMGN - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 1st. Analysts expect Amgen to post earnings of $4.18 per share and revenue of $8.05 billion for the quarter. Amgen has set its FY 2025 guidance at 20.000-21.200 EPS.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Stock Performance

NASDAQ:AMGN traded up $2.82 during midday trading on Tuesday, hitting $285.91. The company's stock had a trading volume of 384,004 shares, compared to its average volume of 2,779,575. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm's 50 day moving average is $301.29 and its 200-day moving average is $292.11. The firm has a market cap of $153.72 billion, a P/E ratio of 37.96, a P/E/G ratio of 2.63 and a beta of 0.59.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.33%. Amgen's payout ratio is currently 126.09%.

Analysts Set New Price Targets

A number of research analysts have issued reports on AMGN shares. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Bank of America raised their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $310.57.

Insider Buying and Selling

In other Amgen news, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company's stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company's stock.

Hedge Funds Weigh In On Amgen

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,468 shares of the medical research company's stock after purchasing an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 at the end of the most recent quarter. Institutional investors own 76.50% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.